A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Bosakitug (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.
- 03 Dec 2024 New trial record